Key result
Anti-leukocyte antibodies show no clinical benefit for improving outcomes in acute stroke.
An abundance of experimental data show that inflammation contributes to cerebral ischaemic injury and that attenuation of the inflammatory response can improve outcome. The two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy. The potential reasons for the failure of these trials are discussed.
No takes yet. Share an insight, caveat, or question.
Kyra J. Becker (2002) conducted a review in Acute stroke. Anti-leukocyte Antibodies (LeukArrest and Enlimomab) was evaluated. Two clinical trials evaluating anti-leukocyte antibodies (LeukArrest and Enlimomab) in acute stroke showed no clinical benefit in limiting the inflammatory response and improving outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: